Leo Pharma and Queensland University agree skin cancer alliance

Leo Pharma has announced a new research alliance with Australia's University of Queensland, focusing on the field of skin cancer.

The three-year collaboration aims to deliver new treatment options to patients suffering from skin cancer, leveraging the expertise and knowledge of both organisations.

Research will cover aspects of skin cancer research in which Leo Pharma is already active, including actinic keratosis and squamous-cell carcinoma, with activities including exploratory clinical trials, basic research, contract research and material transfer agreements.

This comes as part of Leo Pharma's wider strategy to ally with universities and businesses that can complement the company's capabilities in the dermatology field.

Thorsten Thormann, vice-president for new product discovery at Leo Pharma, said: "Our goal is to achieve findings which make us wiser on understanding patients' needs and can be directly applied to our research and development within skin cancer."

Earlier this year, the company was awarded the international growth strategy of the year prize at the European Business Awards.